Nearly 370,000 bottles of a widely prescribed antidepressant have been recalled across the United States after regulators identified elevated levels of a potentially cancer-causing chemical impurity.
The recall affects duloxetine delayed-release capsules distributed by Breckenridge Pharmaceutical and manufactured by Towa Pharmaceutical. According to the US Food and Drug Administration (FDA), testing found levels of N-nitroso-duloxetine above the agency's recommended safety threshold, triggering a nationwide voluntary recall.
